

# Lucia Farina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4894256/publications.pdf>

Version: 2024-02-01

36  
papers

1,350  
citations

361045

20  
h-index

344852

36  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1930  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early serum <scp>TARC</scp> reduction predicts prognosis in advancedâ€stage <scp>Hodgkin</scp> lymphoma patients treated with a <scp>PET</scp>â€adapted strategy. Hematological Oncology, 2020, 38, 501-508.	0.8	8
2	THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, e2016045.	0.5	4
3	High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. Blood Cancer Journal, 2016, 6, e491-e491.	2.8	4
4	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica, 2015, 100, 511-516.	1.7	42
5	Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant. Leukemia and Lymphoma, 2015, 56, 1901-1902.	0.6	3
6	Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. Leukemia and Lymphoma, 2014, 55, 331-336.	0.6	25
7	Plerixafor â€on demandâ€™™: results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. Bone Marrow Transplantation, 2014, 49, 453-455.	1.3	8
8	Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. Leukemia and Lymphoma, 2014, 55, 2032-2037.	0.6	22
9	Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clinical Cancer Research, 2014, 20, 5641-5651.	3.2	31
10	Serum Thymus and Activation-Regulated Chemokine Level Monitoring May Predict Disease Relapse Detected by PET Scan after Reduced-Intensity Allogeneic Stem Cell Transplantation in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 1982-1988.	2.0	14
11	Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 885-890.	2.0	42
12	Current state of art for transplantation paradigms in peripheral T-cell lymphomas. Expert Review of Hematology, 2013, 6, 465-474.	1.0	3
13	Longâ€™term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. European Journal of Haematology, 2013, 90, 340-344.	1.1	2
14	Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. Leukemia and Lymphoma, 2012, 53, 96-102.	0.6	24
15	Phase <scp>II</scp> study of sorafenib in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2012, 158, 108-119.	1.2	36
16	Allogeneic transplantation for Hodgkinâ€™™s lymphoma. British Journal of Haematology, 2011, 152, 261-272.	1.2	22
17	Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience. Leukemia Research, 2011, 35, 712-714.	0.4	14
18	Allogeneic transplantation for lymphoma: long-term outcome. Current Opinion in Hematology, 2010, 17, 522-530.	1.2	8

#	ARTICLE	IF	CITATIONS
19	Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. <i>Blood</i> , 2010, 115, 3671-3677.	0.6	151
20	The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1131-1138.	3.3	111
21	Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. <i>Haematologica</i> , 2009, 94, 654-662.	1.7	62
22	Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. <i>Blood</i> , 2009, 113, 4771-4779.	0.6	69
23	Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. <i>Leukemia and Lymphoma</i> , 2008, 49, 2156-2162.	0.6	143
24	Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 3303-3303.	0.6	26
25	Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2007, 48, 1496-1501.	0.6	14
26	Current role of allogeneic stem cell transplantation in follicular lymphoma. <i>Haematologica</i> , 2007, 92, 580-582.	1.7	1
27	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. <i>Leukemia</i> , 2007, 21, 2316-2323.	3.3	142
28	Molecular Methods Used for The Detection of Autologous Graft Contamination in Lymphoid Disorders. <i>Methods in Molecular Medicine</i> , 2007, 134, 179-196.	0.8	1
29	CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. <i>Experimental Hematology</i> , 2006, 34, 721-727.	0.2	25
30	Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. <i>Experimental Hematology</i> , 2005, 33, 920-927.	0.2	40
31	The role of the tumor microenvironment in hematological malignancies and implication for therapy. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 1581.	3.0	50
32	Effect of Age and Previous Autologous Transplantation on Nonrelapse Mortality and Survival in Patients Treated With Reduced-Intensity Conditioning and Allografting for Advanced Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 6690-6698.	0.8	58
33	Immune-mediated attack in relapsed Hodgkin's lymphoma. <i>Lancet, The</i> , 2005, 365, 1906-1908.	6.3	14
34	Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes. <i>Journal of Clinical Oncology</i> , 2004, 22, 1460-1468.	0.8	116
35	Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease.. <i>Blood</i> , 2004, 104, 808-808.	0.6	5
36	Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 791-793.	1.3	10